Evidence map›Paper›PMID 33198632›Full record

ArticleBMC gastroenterology2020

HER2 gene assessment in liquid biopsy of gastric and esophagogastric junction cancer patients qualified for surgery.

Anna Grenda, Kamila Wojas-Krawczyk, Tomasz Skoczylas, Paweł Krawczyk, Jadwiga Sierocińska-Sawa, Grzegorz Wallner, Janusz Milanowski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Significance of concurrent evaluation of HER2 gene amplification and p53 and Ki67 expression in gastric cancer tissues.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Novel biomarkers for early detection of gastric cancer.World journal of gastroenterology · 2023
    Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Anna GrendaChair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland. an.grenda@gmail.com.ORCID http://orcid.org/0000-0002-2112-8092
Kamila Wojas-KrawczykChair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland.
Tomasz SkoczylasII Chair and Department of General and Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Medical University of Lublin, Staszica 16, 20-080, Lublin, Poland.
Paweł KrawczykChair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland.
Jadwiga Sierocińska-SawaLaboratory of Pathomorphology, Independent Public Clinical Hospital No. 1 in Lublin, ul. Staszica 11, 20-081, Lublin, Poland.
Grzegorz WallnerII Chair and Department of General and Gastrointestinal Surgery and Surgical Oncology of the Alimentary Tract, Medical University of Lublin, Staszica 16, 20-080, Lublin, Poland.
Janusz MilanowskiChair and Department of Pneumology, Oncology and Allergology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland.
Medical University of Lublin · PL1 Military Clinical Hospital with Outpatient Clinic · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmplification of HER2 gene (ERBB2) and overexpression of HER2 protein on cancer cells are found in 10-26% of gastric cancer (GC) and esophagogastric junction cancer (EGJC). Gene copy number variation (CNV) could be detected in these patients in liquid biopsy and in cancer cells.

methodsWe analysed HER2 gene CNV used qPCR method in 87 sera collected from GC and EGJC patients before surgical treatment and in 40 sera obtained from healthy donors. HER2 gene CNV was also assessed in formalin-fixed paraffin-embedded (FFPE) tumor tissue. Furthermore, we assessed the number of HER2 gene copies and HER2 expression in cancer cells using the fluorescent in situ hybridization method (FISH) and immunohistochemistry (IHC).

resultsWe found that the HER2 gene copy number in liquid biopsy was higher in GC and EGJC patients compared to healthy people (p = 0.01). Moreover, EGJC patients had higher number of HER2 gene copies than healthy donors (p = 0.0016). HER2 CNV examination could distinguish healthy individuals and patients with gastric or esophagogastric junction cancers with sensitivity and specificity of 58% and 98% (AUC = 0.707, 95% CI 0.593-0.821, p = 0.004). We found that patients with a high copy number of the HER2 gene in the tumor tissue assessed by qPCR (but not by FISH) have significantly more often a high number of HER2 gene copies in liquid biopsy (p = 0.04).

conclusionsWe suggested that HER2 testing in liquid biopsy could be used as an auxiliary method to analysis of HER2 status in tumor tissue in gastric or esophagogastric junction cancers.

Indexed as

Genes, erbB-2Stomach NeoplasmsBiomarkers, TumorDNA Copy Number VariationsErb-b2 Receptor Tyrosine KinasesEsophagogastric JunctionGene AmplificationHumansIn Situ Hybridization, FluorescenceLiquid BiopsyBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesEsophagogastric cancerGastric cancerHER2 copy numberLiquid biopsy

Identifiers

PMID33198632
PMCPMC7670771
OpenAlexW3106423250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.